Beroni Group Limited (NSX:BTG) Appointment of Non-Executive Director
NSX:BTG) an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has appointed Mr Nicholas Ong as an independent non-executive director of the Company with effect from 1 March 2021. Mr Ong will also chair the Audit Committee of the Company.
Nicholas brings 16 years experience in listing rules compliance and corporate governance. Nicholas is a Fellow of the Governance Institute of Australia and Fellow of Institute of Chartered Secretaries and Administrators. He holds a bachelor degree in Banking and Finance from Murdoch University and a Master of Business Administration from the University of Western Australia. He worked as company secretary and director to various listed companies.
Sydney, Australia – Beroni Group an Australia-based diversified biopharmaceutical enterprise today announces that it has completed its majority acquisition of the Sydney-based anticancer drug development company, PENAO Pty Ltd. As a result of this acquisition, Beroni now owns 60% of PENAO Pty Ltd’s shares. PENAO Pty Ltd was incorporated in 2019 and enjoys the support of the University of New South Wales, Sydney, … Sydney, Australia (ABN Newswire) – Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise today announces that it has completed its majority acquisition of the Sydney-based anticancer drug development company, PENAO Pty Ltd. As a result of this acquisition, Beroni now owns 60% of PENAO Pty Ltd’s shares.